▲ 1 r/Scholar
[Article] Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
DOI/PMID/ISBN: 10.1016/j.annonc.2026.05.693
u/dbcoopernz — 1 day ago